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Health research in sexual minority women has shown that they differ from heterosexual women in prevalence of several physical conditions (Meads et al., 2018; Robinson et al., 2017). For example, a systematic review showed higher rates of chronic pelvic pain and cervical cancer, and lower rates of uterine cancer in lesbians and bisexual women compared to heterosexual women, but no significant difference in rates of polycystic ovarian syndrome, endometriosis, and fibroids (Robinson et al., 2017). Another systematic review demonstrated higher rates of asthma but not cardiovascular disease, despite higher cardiovascular disease risk profiles in lesbians and bisexual women compared to heterosexual women (Meads et al., 2018). It is currently unclear if there are higher rates of breast cancer incidence or not, due to lack of good quality evidence (Meads & Moore, 2013). One study from the US has shown a higher mortality rate from breast cancer (Cochran & Mays, 2012), but it is uncertain whether this is due to higher incidence, poorer access to treatment, or other factors such as avoidance of screening and over-diagnosis of low-grade lesions. Emerging evidence of these different illness rates is somewhat puzzling if there were indeed no physiological differences between sexual minority women and heterosexual women. One explanation may lie in different sex hormone levels. 
Female sexual orientation has been investigated for decades (Balthazart, 2011; James, 2005; Meyer-Bahlburg, 1979; O’Hanlan, Gordon, & Sullivan, 2018), with no firm conclusions drawn about why women may become heterosexual, bisexual or lesbian, though there has been a suggestion that prenatal testosterone levels may influence life-long sexual orientation (Balthazart, 2011).  Potential correlations between sex hormones and sexual orientation have been approached in three main ways. There has been investigation of differences in brain sexual differentiation that may lead to lasting differences in hormonal regulation (Downey et al., 1987). A second route has been by investigating organizational effects of any alteration of the prenatal hormone environment in heterosexual and homosexual people (Balthazart, 2011), for example by looking at second and fourth finger ratios (2D:4D ratios). Thirdly, and of relevance to this project, there has been investigation of activational effects of sex hormones from measurement of their levels in post-pubertal homosexual people (Downey et al., 1987).
Some reviews state that prenatal sex hormones are causally associated with sexual orientation of “butch” lesbians (James, 2005; O’Hanlan, Gordon, & Sullivan, 2018), but this seems to be an extrapolation from findings from research about women with congenital adrenal hyperplasia (Stout et al., 2010). A number of researchers have investigated various markers that may be associated with the prenatal hormonal milieu and sexual orientation, such as handedness (Lalumière, Blanchard, & Zucker, 2000) or second and fourth finger ratios (2D:4D ratios) (Swift-Gallant et al., 2020), among various other parameters. A more recent extensive review of sexual orientation controversies discusses differences in genetic and hormonal pathways and whether either may have a part to play in causation of sexual orientation (Bailey et al., 2016). While the role of hormones in mammalian (including human) sexual differentiation is clear, its role in sexual orientation is less clear.
Historically, much of the research into the biological basis of sexual orientation has also failed to consider the place of bisexual women. Studies have tended to either consider bisexuality as a subset of homosexuality or disregard it entirely. Therefore, in research studies, bisexual women could fall into either homosexual or heterosexual groups depending on how they were perceived by the researcher (Van Wyk & Geist, 1995).
There have been several reviews of sex hormone levels and female sexuality in adulthood, but no systematic reviews.  An early review by Meyer-Bahlburg (1979) concluded that the majority of female homosexuals have normal sex hormone levels after puberty but a third have elevated androgen levels. It is unclear as to how it was discerned that “a third of the subjects studied had elevated androgen levels” as many of the included papers were on transsexuals not lesbians and the normal levels and cut-off used were not clear. Meyer-Bahlburg also stated that variation in adult androgen levels did not affect sexual orientation. Subsequent reviews focused more on issues of trying to extrapolate results from mammals to humans (Birke, 1981) or discussed potential confounding effects of environmental stress (Banks & Gartrell, 1995).
If there is a difference in hormone levels between lesbian, bisexual, and heterosexual women, it is unclear which hormones would be involved, if there is a hormonal “threshold” which must be met, and if it applies to all (Balthazart, 2011). There are two primary sources of sex steroids: ovaries and adrenal glands and the role of each may vary. It may also be that any differences in hormones found are incidental, secondary, or confounding, rather than causative, or affect subgroups of sexual minority women only, such as those who look or pass as more “masculine.” 
It could also be that lesbian practices (or other factors) might lead to changes in sex hormone levels. Similarly, higher levels of chronic stress in society might lead to lower average hormone levels, including for sex hormones such as luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin, progesterone and testosterone, and higher levels of estrogen (​https:​/​​/​www.psychologytoday.com​/​gb​/​basics​/​estrogen" \o "Psychology Today looks at estrogen​). Most research in this area is on non-human animals. 
This systematic review evaluates all published human research on sex hormone levels in sexual minority women compared to heterosexual women.
METHOD
This systematic review was conducted according to a prospective protocol which was lodged with PROSPERO (CRD42017072436) in September 2017.
Inclusion Criteria
Studies were eligible using the following inclusion criteria: (1) Population: sexual minority women self-described as; lesbian or bisexual, women who described themselves as having sex with women (WSW), or having sex with women and men (WSWM); or women co-habiting or married to women, and who were identified as women at birth, and are not taking exogenous sex hormones. (2) Exposure: any sex hormones as reported in included papers, including (but not limited to) androstenedione, estradiol, luteinizing hormone, pregnanediol, progesterone, and testosterone; (3) Comparator: heterosexual women or women self-describing as only having sex with men or married to men; and who were identified as women at birth, and are not taking exogenous hormones. (4) Study design: any comparative studies including randomized controlled trials, experimental studies, cohort studies, case-control studies, cross-sectional analyses, or secondary studies with data of interest. Studies had to contain primary data and be peer-reviewed. Only studies published between 1969 and 2019 were eligible. There were no restrictions on setting or language. Studies were excluded if: the sexual orientation and/or behavior of women were not clear; there was no comparison with heterosexual women; there were no outcomes of interest; or if they were opinions, editorials, conference abstracts, or case reports. Although not specified in the protocol, studies would have been excluded if all participants were taking exogenous hormones (e.g., transgender women who were born male and were taking estrogen supplements).
Search Strategy, Study Selection and Data Extraction
Searches were conducted by one reviewer (AH) and checked by another (CM). Search terms and appropriate synonyms (as MeSH terms and text words) were developed based on population and exposures. Six databases (platforms) were searched - British Nursing Index (Ovid), Cochrane Central (Cochrane Library), Medline (Ovid), Embase (Ovid), PsycInfo (Ovid), and Science Citation Index (Web of Science). The same search terms were used for each database but adapted where necessary. A full table of search terms can be found in Online Supplement Appendix 1. Searches were conducted up to June 2018, and redone using the same search terms and databases in May 2019. There were no language restrictions. All titles found by the above search were assessed for inclusion and abstracts read. Reference lists of relevant reviews and accepted studies were also hand searched to identify any relevant papers not found by database searching. We also checked studies on lesbian health used in other projects because titles and abstracts may not have mentioned the measurement of relevant sex hormones. If any titles and abstracts had relevant information or there was uncertainty, the full study was read and either accepted for the systematic review or rejected based on the above inclusion and exclusion criteria. Full-text assessment to determine inclusion in the systematic review was carried out by two reviewers (AH, CM). Any disagreements were resolved by discussion. A standard form was devised prior to data extraction and quality scoring, based on the content of the papers and the aims of the review. Data were extracted by one reviewer (AH) and checked by another (CM). No authors were contacted about data discrepancies.
Quality Assessments
Studies were appraised for selection, performance, attrition, and detection biases (CM), and reported in the categories of risk of bias, study design issues, and whether the study would be representative of the general population. There is no single validated checklist that would be appropriate for all of the studies due to the diverse study designs so a formal quality assessment tool was not used. 
Data Analysis
Results for plasma, saliva, and urinary analyses were tabulated separately by the different hormones measured. Results for women with medical conditions were assessed separately to those without conditions. Meta-analysis was conducted, using RevMan version 5.3, on hormone levels where five or more studies reported results in a similar way. Where multiple sexual minority subgroups were present, the same heterosexual women comparator was used. Heterogeneity was assessed using the I2 test, using established thresholds. Subgroup analysis was performed where relevant, according to sample type (blood, saliva, urine), and presence or absence of contraceptive pill use, inclusion of postmenopausal women, and sample taken in the post-luteal phase.
RESULTS
From 1236 citations, 104 abstracts were selected, of which 24 full papers were available and were read. Fourteen studies were included in the narrative synthesis and nine in the meta-analyses. See Online Supplement Figure 1 (PRISMA flow chart) and Online Supplement Table 1 (excluded studies with reasons).
Study Characteristics
The 14 studies were published between 1970 and 2016, and are detailed in Table 1. Study designs used were case-control (n = 6), cross sectional (n = 6) and cohort (n = 2), see Online Supplement Table 2 (quality assessment of included studies). Studies were all published in English and originated from: USA (n = 6), UK (n = 5), Taiwan (n = 1), Canada (n = 1) and the Netherlands (n = 1). Funding sources were wide ranging, although four had no details on study funding. Recruitment methods varied with most studies occurring outside of the healthcare environment (n = 12), but one was performed in a gynecology outpatient clinic (Agrawal et al., 2004) and one in two fertility clinics (Chen et al., 2014). Participants were recruited by a variety of methods, including advertising, word of mouth, or consecutive patients; and in some studies a combination was used. Two early studies gave no recruitment details (Gooren, 1986; Loraine et al., 1970). The number of sexual minority women included in the primary studies ranged from 4 (Loraine et al., 1970) to 254 (Agrawal et al., 2004). Participants were all within adult reproductive age range (15 - 45) except one early study, which included participants up to 55 years old (Griffiths et al., 1974), without clarification of numbers related to menopausal status. Sexual minority status was determined by self-reporting of: self-identified orientation, history of sexual behavior, and/or feelings of sexual attraction. Five studies also used a numerical scale of sexual orientation or sexual preference (Dancey, 1990; Downey et al., 1987; Gladue, 1991; Juster et al., 2016; Neave, Menaged, & Weightman, 1999). Six studies specified a length of time participants must have identified as lesbian or bisexual (Chen et al., 2014; Downey et al., 1987; Gartrell, Loriaux, & Chase, 1977; Gladue, 1991; Gooren, 1986; Smith et al., 2011. The minimum time requirement given was 12 months (Downey et al., 1987; Gartrell, Loriaux, & Chase, 1977) and the maximum was exclusive life-long orientation (Gladue, 1991; Gooren, 1986). In one study, lesbians were divided into subgroups according to sexual history (primary, intermediate, and secondary lesbians) (Dancey, 1990) and in one study (Singh et al., 1999) the sexual minority women participants were divided into “butch” and “femme.” Only two of the 14 studies included bisexual women (Diamond & Wallen, 2011; Juster et al., 2016), with one grouping them with lesbian women (Juster et al., 2016) and the other reporting results for bisexual women separately (Diamond & Wallen, 2011). Heterosexual women were the comparator group in 12 studies, one study used a comparator population of women who did not identify as lesbian or bisexual (Diamond & Wallen, 2011), and one study used reference ranges from textbooks and results from a previous study (Griffiths et al., 1974). 
In one study, self-reported information and blood test results were examined by a reproductive endocrinologist (Griffiths et al., 1974). Hormones were measured in plasma (n = 9), saliva (n = 4), and urine (n = 2), one study reported both plasma and salivary hormone results (Juster et al., 2016). Hormones measured included 17-oxosteroids (n = 1), androstenedione (n = 5), DHEAS (n = 2), epitestosterone (n = 2), FSH (n = 2), LH (n = 3), estriol (n = 2), estrone (n = 2), estradiol (n = 10), pregnanediol (n = 2), pregnanetriol (n = 1), progesterone (n = 4), prolactin (n = 2), and testosterone (n = 15). There were 15 results for testosterone because one paper reported results separately for “butch” and “femme” women (Singh et al., 1999). Timing of hormone sampling was controlled for in some studies by time of day (n = 8) (Diamond & Wallen, 2011; Downey et al., 1987; Gartrell, Loriaux, & Chase, 1977; Gladue, 1991; Juster et al., 2016; Loraine et al., 1970; Neave, Menaged, & Weightman, 1999; Singh et al., 1999) and by point in menstrual cycle (n = 9) (Agrawal et al., 2004; Dancey, 1990; Diamond & Wallen, 2011; Downey et al., 1987; Gartrell, Loriaux, & Chase, 1977; Gladue, 1991; Gooren, 1986; Griffiths et al., 1974; Neave, Menaged, & Weightman, 1999). Some studies noted a medical history of menstrual/endocrine abnormalities (n = 7) (Chen et al. 2014; Downey et al., 1987; Gartrell, Loriaux, & Chase, 1977; Gladue, 1991; Neave, Menaged, & Weightman, 1999; Singh et al., 1999; Smith et al., 2011). Current use of hormonal preparations (e.g. contraceptive pill) was specifically excluded for participants in all studies except one (Juster et al., 2016) and not mentioned in two early studies (Griffiths et al., 1974; Loraine et al., 1970). Hormone levels in polycystic ovarian syndrome (PCOS) patients were measured in three studies (Agrawal et al., 2004; Chen et al., 2014; Smith et al., 2010). All of the participants in Chen et al., (2014) had PCOS but fewer than 10% of the participants in Smith et al., (2010) had PCOS (13/211). The study by Agrawal et al., (2004) gave hormone levels for women with normal ovaries separately from those with PCO and PCOS, but the results were not reported separately in Smith et al., (2011). Five studies provided reference ranges for one or more hormone (Chen et al., 2014; Dancey, 1990; Griffiths et al., 1974; Juster et al., 2016; Smith et al., 2011). Numerical results are presented separately for plasma (n = 9) (see Online Supplement Table 3), saliva (n = 4) (see Online Supplement Table 4), and urine hormones (n = 2) (see Online Supplement Table 5). 

Findings in Healthy Women
Direction of difference in hormone levels in sexual minority women compared to heterosexual women without known ovarian problems, measured in more than one study are shown in Table 2. The two early studies measuring estrone (Griffiths et al., 1974; Loraine et al., 1970) showed significant reductions in sexual minority women compared to heterosexual women. There were mixed results in epitestosterone (n = 2), DHEAS (n = 2), LH (n = 3), estriol (n = 2), and progesterone (n = 4), and no significant difference in levels between sexual minority and heterosexual women in androstenedione (n = 5), FSH (n = 2), and pregnanediol (n = 2) (see Table 2). There were also no differences seen in the single studies that measured 17-oxosteroids (Griffiths et al., 1974), pregnanetriol (Griffiths et al., 1974), and prolactin (Agrawal et al., 2004) in women without known ovarian problems. The one study measuring testosterone in “butch” and “femme” lesbians (Singh et al., 1999) showed a significant increase for the “butch” lesbians compared to “femme” lesbians and compared to heterosexual women, but no significant difference between “femme” lesbians and heterosexual women (of any appearance). 
Exploratory meta-analyses in testosterone and estradiol in women without known ovarian problems were conducted. For testosterone, there was a significant increase in sexual minority women overall (n = 9, SMD = +0.90; 95% CI +0.22 to +1.57, I2 = 84%) (see fig 1) compared to heterosexual women, but no significant increase in the plasma testosterone subgroup results. For estradiol, there was no significant difference overall (n = 7, SMD = -0.03 (95% CI -0.24 to +0.18, I2 = 0%)) or in any subgroup by sampling type (see fig 2). 
Subgroup analysis of the testosterone meta-analysis removing the study using luteal sampling (Dancey, 1990) increased the overall SMD to +1.19 (95% CI +0.47 to +1.91). Subgroup analysis removing the study explicitly including participants using the contraceptive pill (Juster et al., 2016) decreased the overall SMD to +0.63 (95% CI +0.08 to +1.18). Adding in results for bisexual women (Dancey, 1990) decreased the overall SMD slightly to +0.82 (95% CI +0.19 to +1.45). 
All of the subgroup analyses for the estrogen meta-analysis made very little difference to the overall result. The only study enrolling participants over the age of 50 (who may have been menopausal) (Griffiths et al., 1974) did not contribute to either meta-analysis. 
Results in Women with Polycystic Ovary Syndrome. 
Three studies included women with PCOS (Agrawal et al., 2004; Chen et al., 2014; Smith et al., 2010). As Smith et al. (2011) did not give results for sexual minority women with PCOS separately to those without PCOS, and there were fewer than 10% of women with PCOS, their results are given in the section above. Agrawal et al. (2004) gave results separately for women with PCOS and all participants in Chen et al. (2014) had PCOS. For sexual minority women with PCOS, there were statistically significantly lower levels of estradiol in one study (Chen et al., 2014) but not in the other (Agrawal et al., 2004), and higher levels of testosterone, androstenedione, and free androgen index in one study (Agrawal et al., 2004), but not in the other (Chen et al., 2014), compared to heterosexual women. There were no significant differences found in levels of DHEAS (Agrawal et al., 2004), FSH (Agrawal et al., 2004; Chen et al., 2014), LH (Agrawal et al., 2004; Chen et al., 2014), and prolactin (Agrawal et al., 2004). 
DISCUSSION
Main Findings
There has been disappointingly little research into sex hormone levels in sexual minority women. Our findings suggest little discernible difference in plasma hormone levels between sexual minority and heterosexual women except for possibly higher testosterone levels, and only when combining blood, saliva and urine results across studies which were small with considerable variation in methods of hormonal data collection. If there are higher rates of testosterone in sexual minority women, the current evidence is not sufficient to determine whether this is in a subset or not. Also, the testosterone levels may be an incidental finding rather than causative of health differences. There were inconsistent results in women with PCOS.   
Strengths and Limitations
Strengths included protocol preregistration in the PROSPERO database, careful presentation of numerical results, inclusion of global data from a variety of sources, and a search for any relevant studies from the last 50 years. Methods of hormone assays have changed over time but each study used the same methods for all of their participant groups. Therefore, as we looked for relative differences between groups within each study and used standardized mean differences in the meta-analyses, absolute differences in measurement methods across studies will not impact on the results. However, we cannot be certain that each of the studies measured hormones in the same part of the menstrual cycle in each participant. Where studies had relatively large samples, hopefully these differences would cancel each other, but in small sample sizes there may be consistent differences because of this. It would be uncertain as to which direction these differences would lie. Also, participants in most of the studies were not explicitly asked if they had PCOS or even congenital adrenal hyperplasia (CAH), both of which can affect testosterone levels. Participants in some studies were split into subgroups of sexual minority status, such as primary, intermediate, or secondary lesbians (for definitions see Online Supplement Table 2) (Dancey, 1990) or "butch" and "femme" (Singh, Vidaurri, Zambarano, & Dabbs, 1999), with little justification, and results presented separately, thereby diluting the main effect of sexual minority vs heterosexual women. Therefore we cannot tell from the small amount of studies so far whether the slightly higher testosterone levels found in the all sample meta-analysis would apply to all lesbians and bisexual women or to a subgroup. It is uncertain as to how any subgroups would be defined. 
Interpretation
There have been no recent systematic reviews of sex hormone levels in sexual minority women. Other studies are consistent with some of the findings, for example Pearcey, Docherty, & Dabbs (1996) found that when measured in butch/femme pairs, “butch” lesbians had higher testosterone levels than their partners who rated themselves as more “femme,” which is similar to the findings in one of our included studies (Singh, Vidaurri, Zambarano, & Dabbs, 1999). However, when combined results for all “butch” partners were compared to all “femme” partners, no significant differences were seen, suggesting that the relative rather than absolute difference is more important, or that the sample size was too small to determine absolute differences in testosterone levels. The heterogeneity of findings was of particular importance in the testosterone findings, where there was some statistically significant evidence of a relationship between androgens and sexual orientation. However, the problem is that there are a number of endocrine conditions that might affect levels of androgens (such as CAH, PCOS, and oral contraceptive or menstrual regulation use), and thus it would be crucial that these variables are controlled for, which was not consistently the case. In the aforementioned study by Singh et al. (1999) participants were not explicitly asked if they had PCOS or even CAH. They were not asked whether they had congenital androgen insensitivity syndrome (CAIS), a condition that effectively makes androgen action impossible, regardless of androgen levels. Thus, the composition of the sample in relation to endocrine factors that would affect androgen levels is unknown. Similarly, in Smith et al. (2011), which did include women with PCOS, these results were not presented separately as they made up only 10% of the sample, thus confounding any relationship between testosterone and sexual minority status.
Implications for Policymakers
If the tentative finding of higher levels of testosterone in sexual minority women were confirmed, higher rates of conditions associated with higher testosterone levels such as PCOS might be expected to be observed, although a recent systematic review has not demonstrated this (Robinson et al., 2017). Therefore, any clinical implications remain currently unclear. Also, finding a difference tells us nothing about the direction of causality. Testosterone levels in the blood can be raised indirectly by stress and there has been much work around minority stress in sexual minorities (Meyer, 2003). Thus, it is unclear if our tentative finding of higher testosterone levels is because of minority stress, another cause, or merely an incidental finding. More clarity is required before any implications for health in sexual minority women can be discussed. 
Implications for Research
There has been very little research into sex hormone levels in sexual minority women so far and most previous studies have had small sample sizes. In the 40 years since its publication, research seems not to have progressed much further than the Meyer-Bahlburg (1979) review. There also appears to be very little information on variations of androgen and estrogen receptor sensitivity. A large, well conducted study is needed to establish sex hormone levels in sexual minority women compared to heterosexual women so that potential influences on the health of sexual minority women can be estimated. This could also measure variations of androgen and estrogen receptor sensitivity. Using an online two group sample size calculator, at 95% CI (alpha of 0.05), beta of 2 and power of 80%, and means and SDs taken from the testosterone Forest plot (mean 17.4, SD 6.27 lesbian, mean 14.7 heterosexual group), we estimate that a single study which could look at all hormone profiles should have 170 participants, 85 in each group, which is fewer than in the Forest plot, but much larger than almost all of the included studies.
It may be possible to use cohort data, for example from the Avon Longitudinal Study of Parents and Children (​http:​/​​/​www.bristol.ac.uk​/​alspac​/​​) (ALSPAC) study, to investigate links between sex hormone and receptor sensitivity levels and sexual orientation.  This large cohort study enrolled participants before birth, recorded adolescents' sexual orientation at age 15 years, and collected blood samples at various ages, including at age 24. Regarding PCOS and other rarer conditions, some questions can only be answered by case-control studies or registry data, which would be feasible if they recorded sexual orientation. An important implication for future research is that sexual orientation, sexual behavior, and cohabitation status should be routinely recorded as part of data collection in research studies, alongside medical records, to allow more large scale interpretation of hormone levels, disease patterns, and potential confounders including stress levels. 
Conclusion
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Recruitment	Hormones Measured Method(Reference ranges)	Age Range(Moderators Controlled for)	Conditions Related to Hormones Levels Measured	Funding
Agrawal 2004UK	Lesbian women
n=254Consecutive recruiting of women who attended The London Women’s Clinic and Hallam Medical Centre for ovulation induction between November 2001 and January 2003.	Self-identification of orientation and history of sexual behavior discussed in interviews,	Heterosexual women
















Total testosterone(Hyperandrogenism: tT elevated and A (>2.4 ng/mL))	Age range: 20-35 years old(Timing regarding menstrual cycle not specified). (No participants were taking OCP or experiencing menopausal symptoms at time of venipuncture, or had ever been diagnosed with Cushing’s syndrome, androgen-secreting tumors, or congenital adrenal hyperplasia.)	AcneBMIHirsutism
HyperandrogenismOligo-mennor-rhoea
PCOS	Joint grant from Taipei Medical University and Taipei Medical University Hospital and also by the Ministry of Science and Technology, Executive Yuan and Taipei Veterans General Hospital.
Dancey 1990UK
	Lesbians (n=30) separated into 3 categories: Primary lesbians (n=10), intermediate lesbians
(n=10), secondary lesbians (n=10)#Recruitment by response to advertisements: Letters left in women’s clubs, pubs, and bookshops. Adverts in women’s magazines. Women who responded were given letters to give to their female friends.	Self-definition as lesbian/ heterosexual.Primary emotional/sexual attractions fulfilled by women (lesbians) or men (hetero-sexuals).Corroborated by score on SOM questionnaire.	Heterosexual womenn=10Recruitment same as for lesbians.	Plasma Androstenedione
Estradiol
Progesterone
Testosterone Testosterone/progesterone ratio(Luteal phase





n=7Part of larger longitudinal study to study sexual identity development. Initial sampling at lesbian, gay, and bisexual community events, youth groups, and classes on gender and sexuality issues taught at local colleges and universities	Self-reporting in interviews and online diary throughout longitudinal study.	Non-lesbian and non-bisexual women who either identified as hetero-sexual or did not claim to have a sexual identity. These women had previously identified as lesbian or bisexual at the start of the longitudinal study.
n=8Recruiting the same as for lesbian and bisexual women.	Salivary estradiol	Mean age = 30 years.(Timing of sample collection started 9 days after first day of menstrual period and consistent time of day. No participants were pregnant, breast feeding, or taking OCP at the time of sample collection.)	-	Grant from National Institutes of Child Health and Human Development. University of Utah Research Committee grant.
Downey 1987USA
	Homosexual women
n=7Recruitment by advertisement within a university community.	Kinsey scale score based on partner preference of sexual fantasies and behavior during previous 12 months.	Hetero-sexual women
n=7Recruitment same as for homo-sexual women.	PlasmaAndrostenedione
Testosterone	Age range: 19-29(Timing of venipuncture on days 1-3 of menstrual cycle and between 8-9am on each day. Matching of homosexual and heterosexual participants according to: age, height, weight, level of education, and whether or not they had a live in partner. No participants had irregular menstrual cycles, had used OCP in the previous year, or been exposed to diethylstilbestrol prenatally.)	-	BRSG grant of the Research Foundation for Mental Hygiene; USPHS NIMH Research Scientist Development Award; Research Center Grants
Gartrell 1977USA	Homosexual women n=21Recruitment: referred by local “homophile organizations”.	Sexual behavior included only same-sex partners (homo-sexuals) or opposite sex partners (hetero-sexuals) for the preceding year.	Heterosexual women n=19No details of recruitment.	Plasma Testosterone	Age range homosexual women: 21-35; heterosexual women: 21-33.(Timing of venipuncture on days 1-3 of menstrual cycle and at 8am each day. No participants were taking OCP or had menstrual irregularities.)	-	No details
Gladue 1991USA	Lesbians
n=16Recruited using newspaper ads, posters, referrals from friends and previous volunteers	Categorized by Kinsey scale using information from question-naires and interview data.Only included if exclusive lifelong (since puberty) homosexual or heterosexual history.	Heterosexual women 
n=16Recruitment same as lesbians women.

	PlasmaEstradiol
Testosterone (free and total)(Reference range not given but states results are in normal limits.)	Age range: lesbians 21-32; heterosexual women: 27-21(Timing of venipuncture on day 6 of menstrual cycle and between 1-4pm on one day. No participants used OCP or had known endocrine abnormalities.)	-	Harry Frank Guggenheim Foundation; National Science Foundation Experimental Program to Stimulate Competitive Research; Achieving Science Excellence in North Dakota Project, National Science Foundation Research Experiences for Under-graduates Program.
Gooren 1986Netherlands	Homosexual womenn=6No details of recruitment	Self-reporting of orientation. Lesbians had a life-long history of exclusive or near exclusive homosexual orientation	Heterosexual women
n=6No details of recruitment.	PlasmaLH, Estradiol
Testosterone	Age range: homosexual women: 24-32; heterosexual women: 22-27.(Timing of venipuncture on day 3-5 of menstrual cycle between 8.30-10am. No participants had used hormonal preparations in 15 months before the study began.)	-	No details
Griffiths 1974







Testosterone(Reference ranges: pregnanediol: 6.2-15.6 (luteal)pregnanetriol: 0.3-8.917-Oxosteroids: 17.4-55.9(µmol/24)5epitestosterone: 6.9-61.8 testosterone: 3.5-41.3 (nmol/24hr))	Lesbians age range: 22-55 (Comparator population of an “appropriate age group” Timing of sampling in relation to menstrual cycle was noted for lesbian subjects. Comparator population samples taken at “appropriate stage” of menstrual cycle. Use of OCP was noted and taken into account when reporting results.)	-	Endowment fund of St. Thomas Hospital
Juster 2016Canada	Lesbian womenN=8Bisexual women n=13Recruited as part of a broader research program. Separate advertisements according to sexual orientation.	Self-identification of orientation by responding to one of three separate adverts asking for heterosexual, bisexual or lesbian participants and in telephone consultation.
Corroborated using Klein Sexual Orientation Scale.	Heterosexual women
n=20Recruitment the same as for lesbian and bisexual women.	Salivary fasting estradiol Progesterone Testosterone (Saliva)
Plasma fasting DHEAS (DHEAS range: 1.2-10.4 µmol/l)	Age range: 18-45(Timing of sample collection between 12 noon and 7pm each day, phase of menstrual cycle not stated. Use of oral contraceptive use and phase of menstrual cycle was considered in analysis.)	Blood pressure
BMICholesterol levelInsulin level
Triglyceride level	Canadian Institutes of Health Research.
RP Juster Doctoral Scholarship from The Institute of Aging of Canadian Institutes of Health Research.
Loraine 1970UK	Lesbiansn=4No information on recruitment.	Self-reporting of orientation and sexual behavior.	Heterosexual women
n=not givenMembers of lab the staff who did not admit to homosexual inclinations.	Urinary Epitestosterone FSH, LH
Estradiol
Estriol, Estrone
PregnanediolTestosterone	Lesbians age range: 20-23 (age not given for controls).(Samples taken throughout menstrual cycle.)	-	No information
Neave 1999UK
	Lesbian women
n=14Recruited through homophile organizations and friendship networks.	Self-reporting and score on questionnaire derived from sell scale of sexual orientation.	Heterosexual women 
n=14Recruited from Northumbria University student population and in the community matched to lesbian women in terms of education level and age.	Salivary Testosterone	Age range: Lesbians: 19-43 (mean 26); Heterosexual women: 20-43 (mean 31),(Timing of sample collection according to menstrual cycle and consistent time of day. No participants were taking hormone influencing drugs (including OCP), had abnormal menstrual cycles, or had medical conditions affecting hormone level.)	-	University of Northumbria Small Research Grants Scheme.
Singh 1999USA	Lesbian women (n=33) separated into “butch” (n=17) and “femme” (n=16) categories according to score on personal history questionnaire.Recruited by “Snowball”/networking technique to find friends/acquaintances of researchers who then recruited more participants by word of mouth.	Self-identification as lesbian or heterosexual	Heterosexual women
n=11Same as for lesbian women	Salivary Fasting:Testosterone	Age range: 25-45(Timing of sample collection at 7-9am each day, phase of menstrual cycle not stated. No participants were taking OCP or had known ovarian problem.)	BMIAge at menarche	National Science Foundation Grant
Smith 2010USA	Lesbian women
n=114Recruitment using participants of the ESTHER Project who agreed to be contacted about further studies. Recruited to original study by local advertisement and community events	Self-identified as non-heterosexual and reported only or primarily having emotional, physical, and romantic attraction towards women within the past 5 years or were in relation-ships with only or primarily women within the past 5 years.	Heterosexual women n=97Self-identified as heterosexual/ straight and only had male partners since the age of 18.	Plasma Fasting:Androstenedione
Testosterone(Biochemical hyper-androgensism: tT ≥3.4ng/mL and A >2.4ng/mL)	Age range: 35-45(Venipuncture phase of menstrual cycle not stated. No participants were using OCP at time of venipuncture, displayed menopausal symptoms, or had a previous diagnosis of Cushing’s syndrome, androgen secreting tumors, congenital adrenal hyperplasia.)	AcneBMIHirsutism
Infertility
PCOS
Oligo-menorrhea	ESTHER Project funded by National Lung, Blood and Heart Association. PCOS study funded by ESTHER Project, Lambda Foundation and Lesbian Health Fund (Gay and Lesbian Medical Association).

Key: #Primary lesbians: Never had heterosexual experiences or interest, scored less than 20 on the heterosexual component of SOM. Intermediate lesbians: Prior heterosexual experience or interest and scored less than 20 on the heterosexual part of the SOM. Secondary Lesbians: Prior heterosexual experience or interest and scored more than 20 on the heterosexual part of the SOM (Dancey et al, 1990).  
Hormones: A: androstenedione; DHEAS: dehydroepiandrosterone sulphate; E2: estradiol; FAI: free androgen index (testosterone/ sex hormone binding globulin x100); FSH: follicle stimulating hormone; L2: luteinizing hormone; P: progesterone; T: testosterone; fT: free testosterone, tT: total testosterone.
Abbreviations: ESTHER – BMI – body mass index, BRSG – Biomedical Research support Grant, Epidemiologic Study of Health Risk. Nmol – nanomoles, OCP – oral contraceptive pill, PCO – polycystic ovaries, PCOS – polycystic ovary syndrome, SOM - sexual orientation method, µmol – micromoles, USPHS NIMH – United States Public Health Service National Institute for Mental Health


Table 2. Hormone Levels, Showing Statistically Significantly Increased (↑), Decreased (↓), Same Levels (→), or Not Measured (…) in Sexual Minority Women Compared to Heterosexual Women Without Known Ovarian Problems
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Search Terms Used and Search Strategy for At Least One Database

Search Terms Used on First and Second Round of Literature Searching 
(Lesbian OR Bisexual OR Homosexual) AND Hormone OR ?estrogen OR Androgen OR Testosterone OR Progesterone OR LH OR FSH OR GnRH OR ACTH OR CRH OR Activin OR Inhibin


Literature Searching Customized to Each Database.
Database	Customization of Search	Search Type Used
Pubmed	Term “Homosexual” not included as clearly covered in MeSH terms	Title and Abstract
CENTRAL 	-	Titles, Abstracts, Key Words
EMBASE	-	Abstract






































Timing of Hormone Measurement	Fasting		
	Menstrual		
	Diurnal		
Hormone Related Conditions Measured		
Additional Tests/Investigations		




















Online Supplement Table 1: Excluded Studies with Reasons for Exclusion
Author, Year	Title	Reason for Exclusion
Baker et al. 2002	Testosterone, Alcohol and Civil and Rough Conflict Resolution Strategies in Lesbian Couples	No heterosexual control group or normal reference range to use as control
Bancroft et al. 1991	Oral Contraceptives, Androgens and the Sexuality of Young Women: II. The Role of Androgens	Hormonal data only for women using OCP or not. No data grouped by sexual orientation
Birke 2012	Is Homosexuality Hormonally Determined?	Review article
De Sutter et al. 2008	PCOS in Lesbian and Heterosexual Women Treated with Artificial Donor Insemination.	Hormone levels not included in final analysis as too many patients data was missing 
Fleischman et al. 2014	Testing the Affiliation Hypothesis of Homoerotic Motivation in Humans: The Effects of Progesterone and Priming	Progesterone levels not separated according to sexual orientation
Gladue et al. 1984	Neuroendocrine Response to Estrogen and Sexual Orientation	No data on lesbian or bisexual women
James et al. 1977	Significance of Androgen Levels in the Aetiology and Treatment of Homosexuality	Study on males only
Juster et al. 2015	Sexual Orientation Modulates Endocrine Stress Reactivity	No data on sex hormone levels only how sex hormones affect cortisol
Loraine et al. 1971	Patterns of Hormone Excretion in Male and Female Homosexuals	Further discussion of an earlier study already being used in this SR





Online Supplement Table 2: Plasma Hormone Results
Study 
Year	Method 
Timing	Hormone(Units)	Populations and results given as mean and (SD)	P value
Significance	Statistical Test
Agrawal et al.2004	Venipuncture on day 2 or 3 of menstrual cycle.		Lesbians	Heterosexuals	L vs. H1	Two tailed t tests, Mann-Whitney U tests (details not given as to which tests used for each hormone)
			NO 




		DHEAS (µg/ml)	3.7 (0.8)	6.1 (1)	7.4 (1.6)	4.9 (0.9)	4.9 (0.8)	6 (1.2)	NS	NS	
		E2 (pmol/l)	162 (32)	169 (36)	170 (45)	162 (35)	156 (28)	169 (43)	NS	NS	
		FAI	-	3.752	12.032	-	2.52	5.632	<0.01*	<0.001*	
		FSH (IU/l)	7.7 (1.4)	6.9 (1.2)	5.4 (0.9)	7.9 (1.6)	6.5 (1.3)	6 (0.7)	NS	NS	
		LH (IU/l)	4.5 (0.5)	4.8 (0.4)	7.8 (0.9)	4.4 (0.5)	4.8 (0.3)	7.3 (1.0)	NS	NS	
		Prolactin (mIU/L)	412 (56)	364 (40)	376 (40)	340 (43)	365 (34)	362 (34)	NS	NS	
		T (nmol/L)	-	2.032	3.442	-	1.722	2.662	<0.05*	<0.05*	
Chen et al.2014	Fasting venipuncture		Lesbians with PCOS (n=8)	Heterosexuals with PCOS (n=89)	L vs. H	Unpaired t test
		A (ng/ml)	2.4 (1.0)	2.4 (1.5)	0.936	
		E2 (pmol/l)	59.1 (13.4)	129.7 (151.2)	<0.001*	
		FAI	0.08 (0.04)	0.07 (0.11)	0.790	
		FSH (IU/l)	5.7 (1.3)	5.6 (2.1)	0.874	
		LH/FSH ratio	2.20 (0.65)	2.90 (1.80)	0.242	
		LH (IU/l)	12.7 (5.1)	15.1 (8.1)	0.422	
		Prolactin (ng/mL)	21.2 (13.3)	13.3 (6.3)	0.141	
		T (ng/ml)	0.34 (0.13)	0.41 (0.24)	0.432	
Dancey1990	Venipuncture during luteal phase (day 4-9 after ovulation) of menstrual cycle. Ovulation kits used to determine point in cycle.		PL (n=10)	IL (n=10)	SL (n=10)	H (n=10)	ANOVA run across all 4 groups	ANOVA
		A (nmol/L)	8.29 (3.59)	7.69 (2.37)	9.38 (3.72)	9.52 (4.18)	0.69	
		E2 (pmol/L)	408.44 (275.03)	306.8 (128.2)	463.7 (200.04)	424.5 (175.16)	0.31	
		P (nmol/L)	23.7 (15.11)	28.5 (23.37)	25.2 (19.56)	29.9 (29.08)	0.98	
		T (nmol/L)	2.24 (0.58)	1.98 (0.88)	2.58 (1.35)	2.56 (1.30)	0.58	
		T/P (ratio)	0.17 (0.17)	0.17 (0.21)	0.53 (0.75)	0.34 (0.47)	0.90	
Downey et al.1987	Venipuncture between 8 and 9am on 1st, 2nd and 3rd days of menstrual period1. Average of 3 specimens.		Lesbians (n=7)	Heterosexuals (n=7)	L vs. H	t tests
		A (ng/100ml)	112 (19)	124 (36)	NS	
		T (ng/100ml)	32 (12)	32 (5)	NS	
Gartrell et al.1977	Venipuncture at 8am of days 1, 2 and 3 of menstrual cycle3. Average of three samples taken.		Lesbians (n=21)	Heterosexuals(n=19)	L vs. H	Details not given
		T (ng/100mL)	36 (11)	26 (7)	<0.001*	
Gladue1991	Venipuncture on day 6 of menstrual cycle between 1 and 4pm. Two samples taken one hour apart.		Lesbians (n=16)	Heterosexuals (n=16)	Not given	No details
		E2 (pg/ml)	41.4 (14.9)	36.9 (9.2)		
		fT (pg/ml)	1.75 (0.7)	2.31 (1.2)		
		tT (ng/dl)	47 (18)	37 (10)		
Gooren et al.1986	Venipuncture during days 3-6 of menstrual cycle		Lesbians (n=6)	Heterosexuals (n=6)	Not given	No details
		E2 (pg/ml)	36 (9)	34 (10)		
		LH (mIU/ml)	5.2 (1.2)	5.0 (1.0)		
		T (ng/ml)	0.29 (0.11)	0.32 (0.1)		
Juster et al.2016	Fasting venipuncture between 8am and 11am		LB
(n=20)	Heterosexual
(n=20)	LB vs. H	ANCOVA
		DHEAS µmol/l	7.34 (0.64)	5.58 (0.37)	0.027*	
Smith et al.2010	Analysis carried out on blood stored from previous study (fasting venipuncture).		Lesbians (n=114)	Heterosexuals (n=97)	L vs. H	Wilcoxon rank-sum tests
		A (ng/ml)	1.63 (median)	1.51 (median)	0.079	
		T (ng/ml)	1.69 (median)	1.52 (median)	0.069	





Online Supplement Table 3: Saliva Hormone Results
StudyYear	MethodTiming	Hormone(unit)	Population and results given as mean and (SD)	P valueSignificance	Statistical test
Diamond 2010	Daily saliva samples for 10 days at the same time each day starting on day 9 of menstrual cycle.		L (n=5)	B (n=7)	NLB (n=8)	Not given	No details
		E2 (pg/ml)	1.9 (0.5)	1.9 (0.7)	2.2 (1.9)		
Juster 2016	Saliva sample taken between 12pm and 7pm.		LB (n=20)	H (n=20)	LB vs. H	ANCOVA

		E2 (pg/ml)	4.33 (0.42)1	4.58 (4.58)1	NS	
		P (pg/ml)	122.92 (16.67)1	66.67 (16.67)1	<0.05*	
		T (pg/ml)	64.44 (4.44)1	48.89 (4.44)1	0.006*	
Neave 1999	Saliva samples produced at same stage in menstrual cycle at 10am-12pm or 2pm-4pm over 2 months.		Lesbians
(n=13)	Heterosexuals
(n=12)	Homosexual men/women vs. heterosexual men + women	ANOVA
		T (pg/ml)	37.50 (8.33) 1	22.22 (5.56)1	0.06	
Singh 1999	Fasting saliva sample between 7 and 9am		Butch L (n=17)	Femme L (n=16)	H
(n=11)	BuL vs. FL	BuL vs. H	FL vs. H	ANOVA
		T (ng/ml)	4.1 (1.7)	2.5 (0.8)	2.3 (0.9)	<0.001*	<0.001*	0.99	
Hormones: E2: estradiol; P: progesterone; T: testosterone. Populations: B: bisexuals; BuL: butch lesbians; FL: femme lesbians; H: heterosexual women; L: lesbian; LB: lesbians and bisexuals; NLB: no longer lesbian or bisexual identity. Statistics: ANOVA: analysis of variance; ANCOVA: analysis of covariance; NS: not significant 1Data extracted from graphs. *Statistically significant result.
Online Supplement Table 4 - Urine Hormone Results
StudyYear	MethodTiming	Hormone
(Units)	Population and results given as mean and (SD)	P valueSignificance	Test
Griffiths et al.1974	Urine sample timing in relation to menstrual cycle was noted.		Lesbians (n=36)	Reference Range	Not given	No details
		17-O (μmol/24hr)	28.8 (6.9-74.3)	17.4-55.91		
		E1 (nmol/24hr)	8.1 (0-48.3)	Onset of menses:14.8-25.8; Ovulation peak: 40.6-114.4; Luteal: 36.9-84.92		
		E2 (nmol/24hr)	4.4 (0-16.5)	Onset of menses: 0-11; Ovulation peak: 14.7-51.4; Luteal: 14.7-36.72		
		E3 (nmol/24hr)	26.6 (0-118.3)	Onset of menses: 0-51.9; Ovulation peak: 45-186.8; 27.7-294.12		




Loraine et al. 

1970.	48 hour pools of urine produced throughout cycle. Results given as value per 24 hours.		L1
(n=1)	L2(n=1)	L3(n=1)	L4(n=1)	L Mean4(n=4)	H(n=not given)	L vs. H	No details
		E1 (μmol/24hr)	6.7 (2.9)	7.1 (4.5)	1.5 (2.9)	1.1 (2.2)	4.1 (3.1)	9.5 (4.8)	All comparisons <0.05-0.001*	
		E2 (μmol/24hr)	3.9 (1.7)	3.7 (3.2)	1.1 (2.4)	0.5 (0.5)	2.3 (2.0)	3.5 (2.4)	L1,L2 p=NS, L3,L4  p<0.001*	
		E3 (μmol/24hr)	11.0 (6)	6.5 (4.4)	13.6 (9.7)	3.8 (2.2)	8.7 (5.6)	9.7 (6.5)	L1,L3 p=NS, L2 p<0.01, L4 p<0.001	
		FSH (IU/24hr)	9.0 (7.3)	10.4 (13.1)	3.6 (2.0)	6.0 (4.9)	7.3 (6.8)	7.3 (1.8)	L1,L2,L4 p=NS L3 p<0.001	
		LH (IU/24hr)	12.4 (22.3)	26.0 (23.2)	37.1 (31.2)	30.7 (29.5)	26.6 (26.5)	11.1 (4.1)	L1 p=NS, L2, L4 p <0.05, L3 p<0.01	
		Pgn2 (mg/24hr)	1.4 (0.7)	2.0 (1.5)	0.5 (0.5)	1.0 (1.0)	1.2 (0.9)	1.2 (1.7)	L1,L3,L4 p=NS, L2 p<0.001	
		T (μmol/24hr)	11 (1.8)	17.3 (2.6)	16.0 (2.5)	30.0 (5.3)	18.6 (3.1)	7.3 (4.3)	All comparisons <0.05-0.001*	
		eT (μmol/24hr)	9.2 (6.5)	18.2 (7.5)	14.1 (10.5)	14.1 (10.2)	13.9 (8.7)	8.9 (4.8)	L1,L3,L4 p=NS, L2 p<0.001	

Key: 17-O: 17-oxosteroids; E1: estrone; E2: estradiol; E3: estriol; FSH: follicle stimulating hormone; L2: luteinising hormone; Pgn2: pregnanediol; Pgn3: pregnanetriol; T: testosterone; eT: epitestosterone. S: Significant. 1Textbook values from “Hormone Assays and their Clinical Applications (Loraine and Bell 1966).2: “Normal” appears to heavily imply heterosexual (or at least not lesbian) but this is not explicit (Brown 1955). 3Textbook values taken from “Gas Chromatographic Determination of Normal Steroids” (Inguilla et al, 1976). 4Individual means given for each lesbian participant (n=4), mean calculated in Microsoft Excel during this systematic review for comparative purposes, values given to one decimal place as in study. *Statistically significant result.


Online Supplement Table 5 - Quality Assessment of Included Studies
Study 	Study Design 	Selection Biases	Performance Biases	Attrition Biases	Detection Biases	Comment 
Agrawal 2004	Cohort Study	Consecutive private clinic sample where SMW attending for different reasons to heterosexual women (single and partnered) and partners of SMW. Possibility of misclassification of single women	As participants from the different groups attending for different reasons, clinical treatment of each group was different. 	Not reported	Hormone assays similar in all groups. Blinding unclear.  Results not given separately for the separate groups. 	Pathologising of SMW by suggesting 80% have a problem (PCO) whereas the medical condition is PCOS – 38% SMW. No ethics permission statement
Chen 2014	Cross sectional analysis	Clinic sample. Unclear if consecutive or not. All have PCOS. 	Unclear if SMW and heterosexual women attending clinic for the same reason	Not reported	Hormone assays similar in all groups. Blinding unclear.	Excluded second control group without PCOS as no indication of sexual orientation. 
Dancey 1990	Case-Control	Volunteer sample from community. Paid £12 plus travel expenses – this may have biased volunteering. 	None reported	The first 10 blood assays from each group were used, possibly introducing bias as later ones discarded	Hormone assays similar in all groups. Blinding unclear.	Unusual separation into ‘primary’, ‘intermediate’ and ‘secondary’ lesbians. Bisexual group excluded as too few. 
Diamond 2010	Cohort Study	Subsample of a larger cohort study investigating sexual identity development. Paid $60 – this may have biased volunteering.	None reported	There had been 33 participants but 13 gave incomplete data. 	Hormone assays similar in all groups. Blinding unclear.	Heteronormative classification of ‘gave up lesbian/bisexual identity’ No ethics permission statement
Downey 1987	Case-Control	Volunteer sample from university community.	None reported	Not reported	Hormone assays similar in both groups. Assays done blind to group. 	No ethics permission statement
Gartrell 1977	Case-Control	Referred sample from ‘homophile organisations’. Unclear where heterosexual sample from. 	None reported	Not reported	Hormone assays similar in both groups. Blinding unclear.	No ethics permission statement
Gladue 1991	Cross-sectional Study	Undergraduate sample volunteering in return for research credits. Possibility of misclassification of sexual orientation.  	None reported	Not reported	Hormone assays similar in both groups. Blinding unclear.	No ethics permission statement
Gooren 1986	Case-Control	Recruitment method not reported. 	None reported	Not reported	Hormone assays similar in both groups. Blinding unclear. Basal hormone assay levels used only	-
Griffiths 1974	Cross-Sectional analysis	Lesbians from membership of a lesbian organisation. Comparator was a group of ‘like-aged mothers of a sample of normal children’. 	Comparator group not sampled at the same time as the lesbian group 	There were 42 lesbian volunteers but only 36 provided hormone samples	Normal values used for comparator.	No ethics permission statement
Juster 2016	Cross-sectional analysis	Subsample from a larger study, recruitment method not reported. Paid $50 CAD – this may have biased volunteering.	None reported	Not reported	Hormone assay similar in both groups. Blinding unclear.	Absolute values for testosterone, estradiol and progesterone not reported. 
Loraine 1970	Case-control study	Lesbian recruitment method not reported. Controls were members of scientific and technical staff. Possibility of misclassification of sexual orientation.  	None reported	Not reported	Lesbian assay results not averaged. 	No ethics permission statement
Neave 1999	Case-Control study	Lesbian volunteers from ‘homophile organisations and friendship networks’ Controls were university students and non-university participants. 	None reported	Testosterone not measured in 2 controls. 	Hormone assay similar in both groups. Blinding unclear. Testosterone levels estimated from graphs. 	-
Singh 1999	Cross-Sectional Analysis	Recruitment through snowballing or networking via friends and acquaintances of the researchers. 	None reported	Not reported	Hormone assay similar in both groups. Blinding unclear.	SMW ‘butch’ and ‘femme’ categories. Study 2 used only. No ethics permission statement
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